Hims & Hers Health stock drops more than 3% after rollout of Hers brand in Australia and upcoming earnings announcement

Traders Union
All News
Stocks
Hims & hers slides 3.13% today

Highlights

Hims & Hers Health will report third quarter 2026 financial results after the close on November 9, 2026.
The company completed the expansion of its Hers brand in Australia, rebranding Juniper and appointing new regional leadership.
Shares of Hims & Hers Health closed at $29.68, down 3.13%, and technicals show mixed momentum with a 70% probability of an upward move to $31.81 in the next five days.

Regional expansion and management changes drive pressure despite platform launch

Hims & Hers Health Inc confirmed it will report third quarter 2026 financial results after the market close on November 9, 2026. The company has completed the rollout of its women-focused Hers brand in Australia following the earlier acquisition of Eucalyptus, including the rebranding of Juniper and key appointments to lead the Australian business. These actions mark the full launch of its platform in the region, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees the stock’s resilience above major moving averages as only a partial buffer against broader selling pressure. He notes the downside gap and overbought momentum indicators as warning signals, especially given the lack of a strong trend and volatility near session midpoint. Kharitonov is skeptical about the company’s completed Hers brand launch in Australia, emphasizing that recent corporate actions have failed to reverse negative sentiment. He cautions that mixed technical signals and an aggressive intraday move require defensive positioning. "Until the stock forms a clearer base above $30.38 with fresh buyer conviction, I remain defensive and see risk of further pullbacks to $27.55 if support breaks."

Viktoras Karapetjanc, expert at Traders Union, views the company’s successful Hers rollout and strategic rebranding in Australia as strong long-term catalysts. He believes the technical setup is positive, with the bullish structure supported by price holding above all key moving averages. Karapetjanc expects upward momentum to persist, especially with a 70% probability assigned to an upside scenario. "With solid fundamentals and supportive sentiment, the bullish structure remains intact, and I see further growth potential if price breaks $30.38."

Jainam Mehta, market strategist, observes that price action is consolidating above strong moving average support despite a volatile session start. He notes that conflicting momentum signals and current overbought conditions present tactical challenges. Mehta points out that a potential breakout above $30.38 could trigger renewed upside, while a reversal below $29.51 would warrant caution. "I would watch for a momentum divergence or failed retest of support as a tactical signal for short-term positioning."

Conflicting overbought indicators and resistance constrain momentum rebound

Hims & Hers Health is currently trading above its 20-day, 50-day, and 200-day moving averages ($29.13, $29.51, and $27.37 respectively), confirming positive short-, medium-, and long-term momentum. For near-term levels, the stock faces resistance at $30.38 and has immediate support at $29.51, with the Ichimoku Kijun at $29.31 acting as further underlying support. Momentum signals are mixed. The Moving Average Convergence Divergence (MACD) shows continued buying interest, but the Average Directional Index (ADX) signals a weak trend. The Relative Strength Index (RSI) at 55.74 suggests moderate strength, yet the Stochastic RSI, Commodity Channel Index (CCI), and Bull/Bear Power (BBP) all indicate overbought conditions, with BBP above zero confirming buyers dominate intraday momentum. The Awesome Oscillator supports a continued upside bias. The stock is trading at $29.68, down $0.96 or 3.13% from the prior close after a downside gap of about $0.81 (2.64%). Price is mid-range for the day, with intraday volatility at 5.78%. This setup reflects early downside pressure followed by a stabilization around the session's midpoint, and signals are pointing to short-term caution given conflicting overbought momentum and lack of a clear directional trend.

Earlier, analysts noted that Hims & Hers Health maintained a bullish technical profile as it expanded internationally, despite facing complex legal and market dynamics. The current setup, marked by stabilization after an initial decline and conflicting momentum signals, highlights the importance of watching for a decisive move above $30.38 or below $29.51 to determine the next directional trend.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.